CD44 and neoplasm: At Day 28, Ad-CD44-N-HIF3α4 significantly suppressed the tumor growth compared to the other adenoviral vectors or PBS ((p < 0.05 for Ad-p53, p<0.01 for the other groups; Figure 9).